Clinical trials: Plaque Psoriasis.
Moderate to Severe Chronic Plaque Psoriasis
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a Phase 3 Study to Compare Pharmacokinetics, Efficacy and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT05495568
- Testing
- CT-P17, EU-approved Humira
- Where
- Estonia
- Volunteers
- 367 people
- Sponsor
- Celltrion
Plaque Psoriasis
Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy profiles of Tazarotene Cream, 0.05% and Tazorac® (Tazarotene) Cream, 0.05% in order to demonstrate bioequivalence and to demonstrate the superiority of the 2 active…
- Trial name
- NCT02160665
- Testing
- Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%
- Where
- United States
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- G & W Laboratories Inc.
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis
The purpose of this study is to compare the safety and effectiveness of a new topical LCD solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms of plaque psoriasis and improving the quality…
- Trial name
- NCT00705900
- Testing
- LCD, calcipotriol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NeoStrata Company, Inc.
Moderate-to-Severe Plaque Psoriasis
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and…
- Trial name
- PSO (NCT04612699)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Psoriasis
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
- Trial name
- NCT00735787
- Testing
- Adalimumab
- Where
- 17 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Abbott
Plaque Psoriasis
A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries
The purpose of this study is to determine how patients use ustekinumab (label-recommended or other/missed dose interval) in Asia-Pacific countries.
- Trial name
- MARCOPOLO (NCT01677598)
- Testing
- No intervention
- Where
- 9 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 169 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis, Psoriasis
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body.
- Trial name
- NCT06357221
- Testing
- Cetaphil
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Plaque Psoriasis
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
The aim of this trial is to assess the efficacy of NYC-0462 Ointment in the Treatment of Plaque Psoriasis.Treatment medication will be administered as follows: A thin layer of study product will be applied to the affected skin…
- Trial name
- NCT00747032
- Testing
- NYC 0462 Ointment
- Sponsor
- Fougera Pharmaceuticals Inc.
Psoriasis
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive…
- Trial name
- NCT00778700
- Testing
- Ruxolitinib Phosphate
- Where
- 28 sites in United States
- Volunteers
- 199 people
- Sponsor
- Incyte Corporation
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Moderate to Severe Plaque Psoriasis
Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
Phase 1, drug-drug interaction study to evaluate the effects of Briakinumab on hte pharmacokinetics of single doses of CYP substrate in subjects with moderate to severe psoriasis.
- Trial name
- NCT01260844
- Testing
- briakinumab
- Volunteers
- 12 people
- Sponsor
- Abbott
Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis [PsA]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine…
- Trial name
- SEC-HOPE (NCT07683065)
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Plaque Psoriasis
AGN-242428 in the Treatment of Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT03339999
- Testing
- AGN-242428
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Psoriasis
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
- Trial name
- NCT00747344
- Testing
- Ustekinumab 45 mg - CP, Ustekinumab 45 mg - after CP
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 121 people
- Sponsor
- Centocor, Inc.
Psoriasis, Atopic Dermatitis
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.
- Trial name
- NCT03381625
- Testing
- BMX-010
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- BioMimetix JV, LLC
Psoriasis Vulgaris
PSOREAL - Managing PSOriasis in the REAL World
Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam…
- Trial name
- PSOREAL (NCT02935582)
- Testing
- Enstilar® aerosol foam, Other topical
- Where
- 3 sites in Canada, Sweden and 1 more
- Volunteers
- 1,214 people
- Sponsor
- LEO Pharma
Psoriasis
A 36-Week Extension to Protocol ISA04-03
The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.
- Trial name
- SPIRIT (NCT00258713)
- Testing
- voclosporin
- Where
- 29 sites in Canada
- Volunteers
- 309 people
- Sponsor
- Aurinia Pharmaceuticals Inc.